Forte Biosciences files prospectus supplement for additional $2.7M ATM offering

Forte Biosciences, Inc.

Filed new prospectus supplement for sale of up to $2.7M of common stock via existing ATM agreement with Ladenburg Thalmann.
Aggregate offering under the ATM agreement remains capped at $25M; previously $7M was registered.
Proceeds to be used for general corporate purposes, including funding existing and potential new clinical programs.
Shares issued under previously effective S-3 registration statement filed May 28, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.